174 related articles for article (PubMed ID: 22154545)
1. Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent.
Hurwitz JL; Stasik I; Kerr EM; Holohan C; Redmond KM; McLaughlin KM; Busacca S; Barbone D; Broaddus VC; Gray SG; O'Byrne KJ; Johnston PG; Fennell DA; Longley DB
Eur J Cancer; 2012 May; 48(7):1096-107. PubMed ID: 22154545
[TBL] [Abstract][Full Text] [Related]
2. SAHA overcomes FLIP-mediated inhibition of SMAC mimetic-induced apoptosis in mesothelioma.
Crawford N; Stasik I; Holohan C; Majkut J; McGrath M; Johnston PG; Chessari G; Ward GA; Waugh DJ; Fennell DA; Longley DB
Cell Death Dis; 2013 Jul; 4(7):e733. PubMed ID: 23868066
[TBL] [Abstract][Full Text] [Related]
3. MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.
Yamamoto K; Seike M; Takeuchi S; Soeno C; Miyanaga A; Noro R; Minegishi Y; Kubota K; Gemma A
Oncol Rep; 2014 Dec; 32(6):2365-72. PubMed ID: 25231602
[TBL] [Abstract][Full Text] [Related]
4. Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis.
Kerr E; Holohan C; McLaughlin KM; Majkut J; Dolan S; Redmond K; Riley J; McLaughlin K; Stasik I; Crudden M; Van Schaeybroeck S; Fenning C; O'Connor R; Kiely P; Sgobba M; Haigh D; Johnston PG; Longley DB
Cell Death Differ; 2012 Aug; 19(8):1317-27. PubMed ID: 22322857
[TBL] [Abstract][Full Text] [Related]
5. Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL.
Yerbes R; López-Rivas A
Invest New Drugs; 2012 Apr; 30(2):541-7. PubMed ID: 21107885
[TBL] [Abstract][Full Text] [Related]
6. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
[TBL] [Abstract][Full Text] [Related]
7. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
[TBL] [Abstract][Full Text] [Related]
8. Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway.
Shi XY; Ding W; Li TQ; Zhang YX; Zhao SC
Med Sci Monit; 2017 Dec; 23():5793-5802. PubMed ID: 29211704
[TBL] [Abstract][Full Text] [Related]
9. FLIP: A Targetable Mediator of Resistance to Radiation in Non-Small Cell Lung Cancer.
McLaughlin KA; Nemeth Z; Bradley CA; Humphreys L; Stasik I; Fenning C; Majkut J; Higgins C; Crawford N; Holohan C; Johnston PG; Harrison T; Hanna GG; Butterworth KT; Prise KM; Longley DB
Mol Cancer Ther; 2016 Oct; 15(10):2432-2441. PubMed ID: 27474150
[TBL] [Abstract][Full Text] [Related]
10. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
You BR; Han BR; Park WH
Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
[TBL] [Abstract][Full Text] [Related]
11. The levels of HDAC1 and thioredoxin1 are related to the death of mesothelioma cells by suberoylanilide hydroxamic acid.
You BR; Park WH
Int J Oncol; 2016 May; 48(5):2197-204. PubMed ID: 26936390
[TBL] [Abstract][Full Text] [Related]
12. The essential role of the mitochondria and reactive oxygen species in Cisplatin-mediated enhancement of fas ligand-induced apoptosis in malignant pleural mesothelioma.
Stewart JH; Tran TL; Levi N; Tsai WS; Schrump DS; Nguyen DM
J Surg Res; 2007 Jul; 141(1):120-31. PubMed ID: 17574045
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
[TBL] [Abstract][Full Text] [Related]
14. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy.
Hoda MA; Mohamed A; Ghanim B; Filipits M; Hegedus B; Tamura M; Berta J; Kubista B; Dome B; Grusch M; Setinek U; Micksche M; Klepetko W; Berger W
J Thorac Oncol; 2011 May; 6(5):852-63. PubMed ID: 21358348
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
Katz SI; Zhou L; Chao G; Smith CD; Ferrara T; Wang W; Dicker DT; El-Deiry WS
Cancer Biol Ther; 2009 Dec; 8(24):2406-16. PubMed ID: 20038816
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials.
Paik PK; Krug LM
J Thorac Oncol; 2010 Feb; 5(2):275-9. PubMed ID: 20035240
[TBL] [Abstract][Full Text] [Related]
17. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity.
Tan J; Zhuang L; Jiang X; Yang KK; Karuturi KM; Yu Q
J Biol Chem; 2006 Apr; 281(15):10508-15. PubMed ID: 16476732
[TBL] [Abstract][Full Text] [Related]
19. The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma.
Laszlo V; Valko Z; Ozsvar J; Kovacs I; Garay T; Hoda MA; Klikovits T; Stockhammer P; Aigner C; Gröger M; Klepetko W; Berger W; Grusch M; Tovari J; Waizenegger IC; Dome B; Hegedus B
J Mol Med (Berl); 2019 Feb; 97(2):231-242. PubMed ID: 30539198
[TBL] [Abstract][Full Text] [Related]
20. An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.
Linton A; Cheng YY; Griggs K; Schedlich L; Kirschner MB; Gattani S; Srikaran S; Chuan-Hao Kao S; McCaughan BC; Klebe S; van Zandwijk N; Reid G
Br J Cancer; 2014 Jan; 110(2):510-9. PubMed ID: 24327015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
